Overview
Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency, sometimes called SCHAD deficiency or HAD deficiency, is a rare inherited metabolic disorder. It is now more commonly referred to as 3-hydroxyacyl-CoA dehydrogenase deficiency or, in its most recognized form, as a cause of congenital hyperinsulinism. The condition affects the body's ability to break down certain fats for energy. Specifically, an enzyme called short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), produced by the HADH gene, does not work properly. This enzyme plays an important role in a process called fatty acid oxidation, which helps the body convert fats into usable energy, especially when food intake is low. Because this enzyme is also involved in regulating insulin release from the pancreas, people with SCHAD deficiency often experience dangerously low blood sugar levels (hypoglycemia) caused by too much insulin being released. This is known as hyperinsulinemic hypoglycemia. Symptoms can appear in newborns or infants and may include seizures, poor feeding, and unusual sleepiness. Without prompt diagnosis and treatment, repeated low blood sugar episodes can cause serious brain injury. Treatment focuses on preventing hypoglycemia through diet, medication, and careful monitoring. The word 'obsolete' in the Orphanet classification reflects updates in how this condition is named and categorized, but the disease itself is real and still recognized by specialists.
Also known as:
Key symptoms:
Very low blood sugar (hypoglycemia)Too much insulin in the blood (hyperinsulinism)Seizures or convulsionsPoor feeding or difficulty eatingUnusual sleepiness or hard to wake upPale or sweaty skinIrritability or fussiness in infantsLiver problems (elevated liver enzymes)Elevated levels of certain fatty acid breakdown products in blood or urineDevelopmental delays if hypoglycemia is not well controlled
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Start the conversation →Latest news about OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency
No recent news articles for OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How often does my child need to eat, and what should I do if they refuse to eat or are sick?,Is diazoxide the right medication for my child, and what side effects should I watch for?,What are the signs of low blood sugar, and how should I treat it at home?,Does my child need a continuous glucose monitor, and how often should blood sugar be checked?,Are there any dietary restrictions or specific foods that help manage this condition?,What is the long-term outlook for my child's development and health?,Should other family members be tested for this condition?
Common questions about OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency
What is OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency?
Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency, sometimes called SCHAD deficiency or HAD deficiency, is a rare inherited metabolic disorder. It is now more commonly referred to as 3-hydroxyacyl-CoA dehydrogenase deficiency or, in its most recognized form, as a cause of congenital hyperinsulinism. The condition affects the body's ability to break down certain fats for energy. Specifically, an enzyme called short chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), produced by the HADH gene, does not work properly. This enzyme plays an important role in a process called fatty acid oxidation, w
How is OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency inherited?
OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency typically begin?
Typical onset of OBSOLETE: Short chain 3-hydroxyacyl-CoA dehydrogenase deficiency is neonatal. Age of onset can vary across affected individuals.